FDA Biosimilars Guidances Address Immunogenicity Studies, European Bridge Data, Analytics
Executive Summary
The agency’s first three draft guidances on biosimilar product development describe how to characterize biosimilar and reference products and extrapolate data on one condition of use to another. FDA says interchangeability is difficult to determine now and will require a switching study.
You may also be interested in...
Sandoz’s Biosimilar Data-Bridging Plans For Zarxio Faced FDA Doubts
FDA 'strongly encouraged' Sandoz to conduct three-way clinical PK/PD study comparing its Zarxio biosimilar to the EU- and U.S.-approved versions of Amgen’s Neupogen; however, the firm succeeded in using only analytical data to justify relevance of studies using the European reference product.
Biosimilars: FDA’s Four-Tiered Assessment Draws Industry Scrutiny
PhRMA asks FDA to remove the categorization of a product as not similar, similar, highly similar, or similar with fingerprint-like similarity.
Biosimilars: FDA’s Four-Tiered Assessment Draws Industry Scrutiny
PhRMA asks FDA to remove the categorization of a product as not similar, similar, highly similar, or similar with fingerprint-like similarity.